SCHEMBL21223541

SCHEMBL21223541

Nc1ccc(-c2c(Cl)cccc2Cl)c(N)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 6/20 0.53
SRC P12931 4/20 0.53
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NPC1 O15118 1/20 0.47
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47
BACE1 P56817 1/20 0.40
MAPK1 P28482 2/20 0.39
ADRA1A P35348 2/20 0.39
PDE3A Q14432 2/20 0.39
CYP2D6 P10635 1/20 0.39
MAOA P21397 1/20 0.39
SCN4A P35499 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
SCN5A Q14524 1/20 0.39
SCN9A Q15858 1/20 0.39
SCN2A Q99250 1/20 0.39
SCN3A Q9NY46 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL264853 0.81 SCN9A (0.51) FGFR1SRCMEN1KMT2ANPC1
SCHEMBL29496134 0.80 NPC1 (0.51) MEN1KMT2ANPC1MAPTRAB9A
SCHEMBL263446 0.80 NPC1 (0.51) MEN1KMT2ANPC1MAPTRAB9A
SCHEMBL21223370 0.78 ALDH1A1 (0.46) FGFR1SRCMEN1KMT2ANPC1
SCHEMBL21223843 0.78 FGFR1 (0.47) FGFR1SRCMEN1KMT2ABACE1
SCHEMBL21223540 0.73 CYP1A2 (0.48) FGFR1SRCMEN1KMT2ANPC1
SCHEMBL4338538 0.73 FGFR1 (0.71) FGFR1SRCEGFRFGFR2FGFR4
SCHEMBL24671592 0.73 PLAU (0.37) FGFR1SRCMEN1KMT2ANPC1
SCHEMBL29496037 0.73 PLAU (0.37) FGFR1SRCMEN1KMT2ANPC1
SCHEMBL17963888 0.72 NR4A2 (0.41) FGFR1SRCMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210221784-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN UNIVERSITÉ DE STRASBOURG (FR) 2021-07-22 US claimed
EP-3749305-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN Université de Strasbourg (FR) 2020-12-16 EP claimed
CN-111683660-A Compounds and compositions for the treatment of pain 斯特拉斯堡大学 2020-09-18 CN claimed
WO-2019149965-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN UNIVERSITE DE STRASBOURG (FR) 2019-08-08 WO claimed
US-20210221784-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN UNIVERSITÉ DE STRASBOURG (FR) 2021-07-22 US disclosed
EP-3749305-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN Université de Strasbourg (FR) 2020-12-16 EP disclosed
CN-111683660-A Compounds and compositions for the treatment of pain 斯特拉斯堡大学 2020-09-18 CN disclosed
WO-2019149965-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN UNIVERSITE DE STRASBOURG (FR) 2019-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210221784-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN ACHE, TRPV1, OPRL1 FGFR1 3626/4885SRC 638/4885MEN1 4484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.